Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1995 3
1996 2
1997 2
1998 4
1999 13
2000 12
2001 13
2002 13
2003 19
2004 13
2005 15
2006 12
2007 13
2008 12
2009 9
2010 6
2011 12
2012 12
2013 13
2014 12
2015 12
2016 8
2017 9
2018 11
2019 10
2020 5
2021 8
2022 7
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

260 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Crossover Randomized Study of Pharmacologic Effects of Ripasudil-Brimonidine Fixed-Dose Combination Versus Ripasudil or Brimonidine.
Tanihara H, Yamamoto T, Aihara M, Koizumi N, Minami H, Kojima S, Isobe T, Kanazawa M, Suganami H; K-232 Clinical Study Group. Tanihara H, et al. Adv Ther. 2023 Aug;40(8):3559-3573. doi: 10.1007/s12325-023-02534-w. Epub 2023 Jun 18. Adv Ther. 2023. PMID: 37330927 Free PMC article. Clinical Trial.
Subjects received twice-daily instillation of RBFC ripasudil brimonidine (group A), ripasudil brimonidine RBFC (group B), or brimonidine RBFC ripasudil (group C). ...Transient morphologic changes in corneal endothelial cells occurred for up to several hours w …
Subjects received twice-daily instillation of RBFC ripasudil brimonidine (group A), ripasudil brimonidine RBFC (group B), or …
Randomized Phase IIb Study of Brimonidine Drug Delivery System Generation 2 for Geographic Atrophy in Age-Related Macular Degeneration.
Freeman WR, Bandello F, Souied E, Guymer RH, Garg SJ, Chen FK, Rich R, Holz FG, Patel SS, Kim K, López FJ; BEACON Study Group. Freeman WR, et al. Ophthalmol Retina. 2023 Jul;7(7):573-585. doi: 10.1016/j.oret.2023.03.001. Epub 2023 Mar 10. Ophthalmol Retina. 2023. PMID: 36906177 Free article. Clinical Trial.
PURPOSE: To evaluate the safety and efficacy of repeat injections of Brimonidine Drug Delivery System (Brimo DDS) Generation 2 (Gen 2) containing 400-mug brimonidine in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). ...
PURPOSE: To evaluate the safety and efficacy of repeat injections of Brimonidine Drug Delivery System (Brimo DDS) Generation 2 (Gen 2 …
Interventions for rosacea.
van Zuuren EJ, Fedorowicz Z, Carter B, van der Linden MM, Charland L. van Zuuren EJ, et al. Cochrane Database Syst Rev. 2015 Apr 28;2015(4):CD003262. doi: 10.1002/14651858.CD003262.pub5. Cochrane Database Syst Rev. 2015. PMID: 25919144 Free PMC article. Review.
Topical interventions: metronidazole, azelaic acid, ivermectin, brimonidine or other topical treatments. Systemic interventions: oral antibiotics, combinations with topical treatments or other systemic treatments, i.e. isotretinoin. ...AUTHORS' CONCLUSIONS: There was high …
Topical interventions: metronidazole, azelaic acid, ivermectin, brimonidine or other topical treatments. Systemic interventions: oral …
Evidence on the neuroprotective properties of brimonidine in glaucoma.
Scuteri D, Bagetta G, Nucci C, Aiello F, Cesareo M, Tonin P, Corasaniti MT. Scuteri D, et al. Prog Brain Res. 2020;257:155-166. doi: 10.1016/bs.pbr.2020.07.008. Epub 2020 Aug 6. Prog Brain Res. 2020. PMID: 32988470
OBJECTIVES: this systematic review and meta-analysis aims at assessing the efficacy of brimonidine on visual field deterioration during glaucoma through the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) approach. ...CONCLUSIONS: the evidence o …
OBJECTIVES: this systematic review and meta-analysis aims at assessing the efficacy of brimonidine on visual field deterioration duri …
Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.
Li T, Lindsley K, Rouse B, Hong H, Shi Q, Friedman DS, Wormald R, Dickersin K. Li T, et al. Ophthalmology. 2016 Jan;123(1):129-40. doi: 10.1016/j.ophtha.2015.09.005. Epub 2015 Oct 31. Ophthalmology. 2016. PMID: 26526633 Free PMC article. Review.
The mean reductions (95% credible intervals) in IOP in millimeters of mercury at 3 months ordered from the most to least effective drugs were as follows: bimatoprost 5.61 (4.94; 6.29), latanoprost 4.85 (4.24; 5.46), travoprost 4.83 (4.12; 5.54), levobunolol 4.51 (3.85; 5.24), taf …
The mean reductions (95% credible intervals) in IOP in millimeters of mercury at 3 months ordered from the most to least effective drugs wer …
Brinzolamide-brimonidine fixed combination for the prevention of intraocular pressure elevation after phacoemulsification.
Georgakopoulos CD, Kagkelaris K, Pagoulatos D, Plotas P, Makri OE. Georgakopoulos CD, et al. Eur J Ophthalmol. 2020 Mar;30(2):293-298. doi: 10.1177/1120672118817997. Epub 2018 Dec 10. Eur J Ophthalmol. 2020. PMID: 30526051 Clinical Trial.
AIM: To evaluate the effectiveness of brinzolamide-brimonidine fixed combination to control the intraocular pressure elevation throughout the first 24 h following uncomplicated phacoemulsification cataract surgery. PATIENTS AND METHODS: A total of 62 patients who underwent …
AIM: To evaluate the effectiveness of brinzolamide-brimonidine fixed combination to control the intraocular pressure elevation throug …
Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial.
McLaurin E, Cavet ME, Gomes PJ, Ciolino JB. McLaurin E, et al. Optom Vis Sci. 2018 Mar;95(3):264-271. doi: 10.1097/OPX.0000000000001182. Optom Vis Sci. 2018. PMID: 29461408 Free PMC article. Clinical Trial.
PURPOSE: The aim of this study was to evaluate the safety and efficacy of brimonidine tartrate ophthalmic solution 0.025% for the treatment of ocular redness. ...Adverse events were infrequent, and brimonidine was rated as very comfortable. CONCLUSIONS: Br
PURPOSE: The aim of this study was to evaluate the safety and efficacy of brimonidine tartrate ophthalmic solution 0.025% for …
Brimonidine displays anti-inflammatory properties in the skin through the modulation of the vascular barrier function.
Bertino B, Blanchet-Réthoré S, Thibaut de Ménonville S, Reynier P, Méhul B, Bogouch A, Gamboa B, Dugaret AS, Zugaj D, Petit L, Roquet M, Piwnica D, Vial E, Bourdès V, Voegel JJ, Nonne C. Bertino B, et al. Exp Dermatol. 2018 Dec;27(12):1378-1387. doi: 10.1111/exd.13793. Exp Dermatol. 2018. PMID: 30290018 Clinical Trial.
Characteristic vascular changes in rosacea skin include enlarged, dilated vessels of the upper dermis and blood flow increase. Brimonidine is approved for symptomatic relief of the erythema of rosacea. ...Topical pretreatment with brimonidine tartrate 0.33% g …
Characteristic vascular changes in rosacea skin include enlarged, dilated vessels of the upper dermis and blood flow increase. Brimonidin
Comparisons of efficacy and safety between preserved and preservative-free brimonidine tartrate in glaucoma and ocular hypertension: a parallel-grouped, randomized trial.
Kim KE, Lee CK, Shin J, Kim Y, Rho S. Kim KE, et al. Sci Rep. 2023 Apr 7;13(1):5700. doi: 10.1038/s41598-023-31726-1. Sci Rep. 2023. PMID: 37029145 Free PMC article. Clinical Trial.
This multicenter (four institutions), randomized, investigator-masked, parallel-group clinical trial evaluated and compared the efficacy and safety of preservative-free and preserved brimonidine tartrate 0.15% in open-angle glaucoma and ocular hypertension. ...Systo …
This multicenter (four institutions), randomized, investigator-masked, parallel-group clinical trial evaluated and compared the efficacy and …
Brinzolamide/brimonidine fixed-dose combination bid as an adjunct to a prostaglandin analog for open-angle glaucoma/ocular hypertension.
Topouzis F, Goldberg I, Bell K, Tatham AJ, Ridolfi A, Hubatsch D, Nicolela M, Denis P, Lerner SF. Topouzis F, et al. Eur J Ophthalmol. 2021 Jan;31(1):103-111. doi: 10.1177/1120672119878044. Epub 2019 Oct 9. Eur J Ophthalmol. 2021. PMID: 31595773 Free PMC article. Clinical Trial.
PURPOSE: To evaluate the additive intraocular pressure-lowering effect of twice-daily brinzolamide 1%/brimonidine 0.2% fixed-dose combination (BBFC) as an adjunct to a prostaglandin analog (PGA) in patients with open-angle glaucoma or ocular hypertension insufficiently con …
PURPOSE: To evaluate the additive intraocular pressure-lowering effect of twice-daily brinzolamide 1%/brimonidine 0.2% fixed-dose com …
260 results